Drug Price Trends for GS MICONAZOLE

Average Pharmacy Cost for GS MICONAZOLE

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
GS MICONAZOLE 3 COMBO PACK	00113-0081-00	7.77321	EACH	2026-07-22
GS MICONAZOLE 7 CREAM	00113-0214-29	0.12302	GM	2026-07-22
GS MICONAZOLE 7 CREAM	00113-0825-29	0.12302	GM	2026-07-22
GS MICONAZOLE 3 COMBO PACK	00113-0081-00	7.93271	EACH	2026-06-17

Error:Operation timed out after 1000 milliseconds with 0 bytes received

Market Analysis and Price Projections for GS MICONAZOLE

Last updated: July 27, 2025

Understanding the Miconazole Market Landscape

The global antifungal drugs market, which includes miconazole, is experiencing steady growth. As of 2020, the market was valued at $16.6 billion and is projected to reach $25.0 billion by 2030, growing at a compound annual growth rate (CAGR) of 3.9%[6]. This growth is driven by several factors, including the rising incidence of fungal infections and increased awareness about fungal diseases.

GS MICONAZOLE: A Key Player in the Antifungal Arena

GS MICONAZOLE, a generic version of the popular antifungal drug, has been making waves in the pharmaceutical industry. As an azole antifungal, it offers broad-spectrum activity against various fungal infections affecting the vagina, mouth, and skin, including candidiasis[9].

Mechanism of Action

Miconazole works by inhibiting the synthesis of ergosterol, a crucial component of fungal cell membranes. This inhibition leads to the accumulation of toxic sterols, loss of membrane integrity, and ultimately, growth arrest of the fungal cells[4].

Market Trends and Drivers

Rising Prevalence of Fungal Infections

The increasing prevalence of fungal infections is a significant driver for the miconazole market. According to the Centers for Disease Control and Prevention, approximately 46,000 new cases of invasive candidiasis, a common bloodstream infection, occur each year in the U.S.[6]

Growing Awareness and Healthcare Initiatives

Public and private organizations are increasingly launching initiatives to spread awareness about fungal infections. This heightened awareness is expected to boost the demand for antifungal drugs like miconazole[6].

Technological Advancements

Ongoing research and development in the field of antifungal drugs are leading to more effective and safer formulations. For instance, the azole group, to which miconazole belongs, is known for its improved safety standards and broad spectrum of activity[4].

Price Analysis of GS MICONAZOLE

Current Pricing Trends

As of January 2025, the average pharmacy cost for GS MICONAZOLE 7 CREAM (NDC 00113-0214-29) is $0.13752 per gram[2]. This pricing has shown slight fluctuations over the past few months:

• January 22, 2025: $0.13752/GM
• December 18, 2024: $0.13494/GM
• November 20, 2024: $0.13792/GM
• October 23, 2024: $0.12890/GM
• September 18, 2024: $0.13473/GM

Factors Influencing Price

Several factors contribute to the pricing of GS MICONAZOLE:

1. Manufacturing Costs: The production process and raw material costs significantly impact the final price.

2. Market Demand: As fungal infections become more prevalent, the demand for miconazole may increase, potentially affecting prices.

3. Competition: The presence of other antifungal drugs in the market can influence pricing strategies.

4. Regulatory Policies: Government regulations and healthcare policies can impact drug pricing.

Future Price Projections

A 3.81% overall drug price inflation rate is projected for 2025, which will influence the pricing of NDC 00113-0825[5].

Based on this projection and current market trends, we can expect a slight increase in the price of GS MICONAZOLE in the coming years. However, the exact pricing will depend on various market dynamics and competitive forces.

Competitive Landscape

Key Market Players

The antifungal drugs market is highly competitive, with several major players vying for market share. Some of the key companies in this space include:

• Bayer AG
• Novartis AG
• GSK plc
• Ciron Group
• Actiza Pharmaceutical Pvt. Ltd.[3]

These companies are continuously investing in research and development to improve their product offerings and maintain their market positions.

Generic vs. Branded Miconazole

GS MICONAZOLE, being a generic version, offers a more cost-effective alternative to branded miconazole products. For instance, Monistat, a popular branded version of miconazole, has an average retail cost of $18[8]. In comparison, generic miconazole can be significantly cheaper, especially with discount programs.

Market Segmentation

By Drug Class

The antifungal drugs market is segmented into various drug classes, with azoles (including miconazole) being a dominant segment. The azoles segment is expected to maintain its dominance due to its broad-spectrum activity and improved safety profile[7].

By Application

Miconazole is used to treat various fungal infections, including:

1. Vaginal yeast infections
2. Oral thrush
3. Skin infections (e.g., athlete's foot, jock itch, ringworm)

The vaginal antifungal segment is particularly significant, with miconazole being a popular over-the-counter treatment option.

Regional Market Analysis

The global antifungal drugs market, including miconazole, shows varying trends across different regions:

North America

North America dominates the antifungal drugs market, driven by high healthcare expenditure and advanced healthcare infrastructure[3].

Europe

Europe is another significant market for antifungal drugs, with a growing elderly population contributing to increased demand.

Asia-Pacific

The Asia-Pacific region is expected to show rapid growth in the antifungal drugs market, fueled by improving healthcare access and rising awareness about fungal infections.

Future Market Outlook

The future of the GS MICONAZOLE market looks promising, with several factors contributing to its growth:

1. Increasing Fungal Infections: The rising prevalence of fungal infections, especially in immunocompromised patients, will drive demand.

2. Technological Advancements: Ongoing research may lead to more effective formulations of miconazole.

3. Growing Awareness: Increased awareness about fungal infections and their treatments will boost market growth.

4. Expansion in Emerging Markets: There's significant potential for market expansion in developing countries.

Challenges and Opportunities

Challenges

1. Side Effects: Like all drugs, miconazole can cause side effects, which may limit its use in some patients.

2. Drug Resistance: The development of antifungal resistance is a growing concern that could impact the efficacy of miconazole.

3. Regulatory Hurdles: Stringent regulatory requirements can slow down the approval process for new formulations.

Opportunities

1. Combination Therapies: Developing combination therapies with miconazole could enhance its efficacy and market potential.

2. Novel Delivery Systems: Innovations in drug delivery systems could improve the effectiveness and patient compliance of miconazole treatments.

3. Expanding Indications: Research into new applications for miconazole could open up additional market opportunities.

Key Takeaways

• The global antifungal drugs market, including miconazole, is projected to reach $25.0 billion by 2030, growing at a CAGR of 3.9%.
• GS MICONAZOLE, a generic version of miconazole, offers a cost-effective treatment option for various fungal infections.
• Current pricing for GS MICONAZOLE 7 CREAM averages around $0.13752 per gram, with slight fluctuations observed over recent months.
• A 3.81% overall drug price inflation rate is projected for 2025, which may impact GS MICONAZOLE pricing.
• The azoles segment, which includes miconazole, is expected to maintain its dominance in the antifungal drugs market.
• North America currently dominates the antifungal drugs market, but rapid growth is expected in the Asia-Pacific region.
• Future market growth will be driven by factors such as increasing fungal infections, technological advancements, and growing awareness.
• Challenges include potential side effects and the development of antifungal resistance, while opportunities lie in combination therapies and novel delivery systems.

FAQs

1. What is the primary use of GS MICONAZOLE? GS MICONAZOLE is primarily used to treat fungal infections affecting the vagina, mouth, and skin, including candidiasis.

2. How does the price of GS MICONAZOLE compare to branded versions? GS MICONAZOLE, being a generic version, is generally more cost-effective than branded versions like Monistat.

3. What factors could influence the future price of GS MICONAZOLE? Factors such as manufacturing costs, market demand, competition, and regulatory policies can influence the future price of GS MICONAZOLE.

4. Is the demand for antifungal drugs like GS MICONAZOLE expected to increase? Yes, the demand is expected to increase due to rising prevalence of fungal infections and growing awareness about fungal diseases.

5. What are the main challenges facing the GS MICONAZOLE market? The main challenges include potential side effects, development of antifungal resistance, and regulatory hurdles for new formulations.

Sources cited: [2] [3] [4] [5] [6] [7] [8] [9]